CAS: 6636-78-8; 2-Chloro-3-Hydroxypyridine

上下游产品

CAS号381248-04-0 2-氯吡啶-3-硼酸 | CAS号452972-11-1 2-氯吡啶-3-硼酸频哪醇酯 | CAS号109-09-1 2-氯吡啶 | CAS号109-00-2 3-羟基吡啶 | CAS号89694-54-2 2-溴-3-乙氧基吡啶 | CAS号6298-19-7 2-氯-3-氨基吡啶 | CAS号15128-82-2 3-羟基-2-硝基吡啶 | CAS号38729-14-5 2-nitro-1-oxy-p... | CAS号6602-28-4 3-羟基吡啶-N-氧化物 | CAS号108082-72-0 2-氯-3-苄氧基甲基吡啶 | CAS号52764-11-1 2,6-二氯-3-羟基吡啶 | CAS号15128-85-5 2-氯--3-羟基-4-硝基吡啶 | CAS号478148-60-6 [2,3-C]吡啶,5-羟甲基呋喃 | CAS号478148-62-8 呋喃并[2,3-C]吡啶-5-羧酸 | CAS号208519-38-4 2-Chloro-6-meth... | CAS号18068-82-1 2-Phenylfuro[3,... | CAS号208519-41-9 2-氯-6-(羟基甲基)吡啶-3-醇 | CAS号208519-37-3 2-氯-3-羟基-6-(羟甲基... | CAS号52605-99-9 5,6-二甲氧基烟醛

3-羟基吡啶置于盐酸,水,双氧水体系中,化学反应生成 2-氯-3-羟基吡啶
参考文献:吡ido醇和吡ido醛类似物的研究ⅰ:取代的吡啶醛的合成
标题:吡ido醇和吡ido醛类似物的研究ⅰ:取代的吡啶醛的合成
摘要:报道了3-羟基吡啶-2-醛,3-甲氧基吡啶-2-醛,3-羟基吡啶-4-醛,3-甲氧基吡啶-4-醛及其衍生物和一些新的中间体的制备,纯化和性质.描述了作为潜在的抗结核剂的醛的硫代半咔唑和作为吡pyr醇类似物的3-羟基-4-羟基甲基吡啶和3-甲氧基-4-羟基甲基吡啶的制备.
DOI:10.1016/s0040-4020(01)82610-7

专利信息

专利号:WO-0005212-A1
优先权日:1998-07-21
标 题:3-substituted pyridine compounds and related synthesis
发明人：HOGLEN DEAN KENT
权利人:NOVARTIS AG; NOVARTIS ERFIND VERWALT GMBH; HOGLEN DEAN KENT
摘要:The present invention relates to 3-substituted and 2,3-disubstituted pyridine compounds of formula (I), wherein R1 is C1-C4 haloalkyl and R4 is H, halogen or C1-C4 alkylthio; and acid addition salts thereof which are useful as intermediates in the synthesis of pyridylsulfonylurea herbicides. The invention also relates to arylation of alcohols using a pyridinediazonium salt. More particularly the arylation process of the instant invention relates to the synthesis of 2,3-disubstituted pyridine compounds via anhydrous diazotization of 3-aminopyridines to form a diazonium salt intermediate that is then reacted with the appropriate alcohol to produce the desired product. The invention additionally relates to pyridine-3-diazonium salt intermediates.

专利号:US-6093739-A
优先权日:1997-11-21
标 题:Synthesis of long wavelength absorbing photosensitizers
发明人：JOHNSON CLAIRE K; DOLPHIN DAVID
权利人:UNIV BRITISH COLUMBIA
摘要:The present invention provides for novel therapeutic macrocycle compounds useful in photodynamic therapy that are based on the chlorin ring system. The macrocycle compounds have, in many cases, wavelengths of activation at about 670 nm, characteristics of chlorins, and are stabilized against oxidation by the attachment to the chlorin ring of a structure that comprises one or more exocyclic rings that contribute at least one nitrogen atom. Protonation or covalent modification of this nitrogen atom, or other covalent modification of the one or more exocyclic rings permits optimization of pharmacalogically relevant properties including, for example, solubility. Representative chlorins include the pyridochlorins depicted as follows ##STR1##

专利号:US-6710180-B2
优先权日:1998-07-21
标题 :Diazonium salts which are intermediates for 3-substituted pyridines
发明人：HOGLEN DEAN KENT
权利人:SYNGENTA PARTICIPATIONS AG
摘要:The present invention relates to 3-substituted and 2,3-disubstituted pyridine compounds which are useful as intermediates in the synthesis of pyridylsulfonylurea herbicides. The invention also relates to arylation of alcohols using a pyridinediazonium salt. More particularly the arylation process of the instant invention relates to the synthesis of 2,3-disubstituted pyridine compounds via anhydrous diazotization of 3-amninopyridines to form a diazonium salt intermediate that is then reacted with the appropriate alcohol to produce the desired product. The invention additionally relates to pyridine-3-diazonium salt intermediates.

专利号:US-7687487-B2
优先权日:2007-04-19
标题 :Camptothecin-analog with a novel, “flippedâ€? lactone-stable, E-ring and methods for making and using same
发明人：HAUSHEER FREDERICK H
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) a novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic aents, to subjects in need thereof.

专利号:US-7999090-B2
优先权日:2000-07-07
标 题:Fungal cell wall synthesis gene
发明人：TSUKAHARA KAPPEI; HATA KATSURA; SAGANE KOJI; NAKAMOTO KAZUTAKA; TSUCHIYA MAMIKO; WATANABE NAOAKI; OHBA FUMINORI; TSUKADA ITARU; UEDA NORIHIRO; TANAKA KEIGO; KAI JUNKO
权利人:EISAI R&D MAN CO LTD
摘要:The present invention provides isolated DNA encoding a GWT1 protein having activity to confer resistance of a fungus against a compound of formula Ia, and wherein a defect of a function of the GWT1 protein leads to a decrease in the amount of a glycosylphosphatidylinositol (GPI)-anchored protein in the cell wall of a fungus.

专利号:EP-2007386-B1
优先权日:2006-04-19
标题 :Camptothecin-analog with a novel, flipped lactone-stable, e-ring and methods for making and using same
发明人：HAUSHEER FREDERICK H
权利人:BIONUMERIK PHARMACEUTICALS INC
摘要:The present invention discloses: (i) a novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flippedâ€? E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic aents, to subjects in need thereof.